Diagnostic markers of stroke and cerebral injury and methods of use thereof

A method of diagnosing stroke in a subject, comprising:

• analyzing a test sample obtained from a subject exhibiting one or more symptoms associated with the diagnosis of stroke for the presence or amount of a plurality of markers selected from the group consisting of matrix metalloproteinase-9, one or more forms of von Willebrand factor, vascular cell adhesion molecule, and S-100β, or related markers thereof mimics;
• and
• correlating the presence or amount of said markers in said test sample to the occurrence of a stroke in said subject.

A method of diagnosing stroke in a subject, comprising:

• analyzing a test sample obtained from a subject exhibiting one or more symptoms associated with the diagnosis of stroke for the presence or amount of a plurality of markers selected from the group consisting of matrix metalloproteinase-9, one or more forms of von Willebrand factor, and vascular cell adhesion molecule, or related markers thereof mimics;
• and
• correlating the presence or amount of said markers in said test sample to the occurrence of a stroke in said subject.

A method of diagnosing stroke in a subject, comprising:

• analyzing a test sample obtained from a subject exhibiting one or more symptoms associated with the diagnosis of stroke for the presence or amount of a plurality of markers selected from the group consisting of one or more forms of von Willebrand factor, vascular cell adhesion molecule, and S-100β, or related markers thereof mimics;
• and
• correlating the presence or amount of said markers in said test sample to the occurrence of a stroke in said subject.

A method of diagnosing stroke in a subject, comprising:

• analyzing a test sample obtained from a subject exhibiting one or more symptoms associated with the diagnosis of stroke for the presence or amount of a plurality of markers selected from the group consisting of B-type natriuretic peptide, glial fibrillary acidic protein, interleukin-8, β-nerve growth factor, von Willebrand factor-A1, and C-reactive protein, or related markers thereof mimics;
• and
• correlating the presence or amount of said markers in said test sample to the occurrence of a stroke in said subject.

A method of diagnosing stroke in a subject, comprising:

• analyzing a test sample obtained from a subject exhibiting one or more symptoms associated with the diagnosis of stroke for the presence or amount of a plurality of markers selected from the group consisting of B-type natriuretic peptide, glial fibrillary acidic protein, interleukin-8, creatine kinase-BB, monocyte chemotactic protein-1, and interleukin-1 receptor antagonist, or related markers thereof mimics;
• and
• correlating the presence or amount of said markers in said test sample to the occurrence of a stroke in said subject.

A method of diagnosing stroke in a subject, comprising:

• analyzing a test sample obtained from a subject exhibiting one or more symptoms associated with the diagnosis of stroke for the presence or amount of a plurality of markers selected from the group consisting of B-type natriuretic peptide, glial fibrillary acidic protein, C-reactive protein, creatine kinase-BB, matrix metalloproteinase-9, interleukin-8, and β-nerve growth factor, or related markers thereof;
• and
• correlating the presence or amount of said markers in said test sample to the occurrence of a stroke in said subject.

A method of diagnosing stroke in a subject, comprising:

• analyzing a test sample obtained from a subject exhibiting one or more symptoms associated with the diagnosis of stroke for the presence or amount of a plurality of markers selected from the group consisting of B-type natriuretic peptide, glial fibrillary acidic protein, C-reactive protein, creatine kinase-BB, caspase-3, monocyte chemotactic protein-1, and von Willebrand factor-integrin, or related markers thereof;
• and
• correlating the presence or amount of said markers in said test sample to the occurrence of a stroke in said subject.

A panel comprising a plurality of markers selected to selectively identify the occurrence or nonoccurrence of a stroke in a subject exhibiting one or more symptoms associated with the diagnosis of stroke, wherein said marker(s) are selected to distinguish the occurrence of a stroke in said subject from one or more stroke mimic conditions.

A panel comprising a plurality of markers selected to selectively identify the occurrence or nonoccurrence of an acute stroke in a subject exhibiting one or more symptoms associated with the diagnosis of stroke.

A panel comprising a plurality of markers selected to selectively identify the occurrence or nonoccurrence of a non-acute stroke in a subject exhibiting one or more symptoms associated with the diagnosis of stroke.

A panel according to claim 30, wherein a first set of markers are selected to identify an acute stroke, and a second set of markers are selected to identify a non-acute stroke.

A device comprising a plurality of discretely addressable locations comprising a receptor for one of a plurality of markers selected to selectively identify the occurrence or nonoccurrence of a stroke in a subject exhibiting one or more symptoms associated with the diagnosis of stroke, wherein said marker(s) are selected to distinguish the occurrence of a stroke in said subject from one or more stroke mimic conditions.

A device comprising a plurality of discretely addressable locations comprising a receptor for one of a plurality of markers selected to selectively identify the occurrence or nonoccurrence of an acute stroke in a subject exhibiting one or more symptoms associated with the diagnosis of stroke.

A device comprising a plurality of discretely addressable locations comprising a receptor for one of a plurality of markers selected to selectively identify the occurrence or nonoccurrence of a non-acute stroke in a subject exhibiting one or more symptoms associated with the diagnosis of stroke.

A device according to claim 53, wherein said acute phase reactant is selected from the group consisting of C-reactive protein, E-selectin, insulin-like growth factor-1, intercellular adhesion molecule-1, interleukin-1β, interleukin-1 receptor antagonist, interleukin-6, matrix metalloproteinase-3, matrix metalloproteinase-9, monocyte chemotactic protein-1, transforming growth factor β, tumor necrosis factor α, and vascular cell adhesion molecule, or related markers thereof.